123 related articles for article (PubMed ID: 36778226)
1. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Winslow MM; Petrov DA; Boross G
bioRxiv; 2023 Feb; ():. PubMed ID: 36778226
[TBL] [Abstract][Full Text] [Related]
2. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Szamecz M; Winslow MM; Petrov DA; Boross G
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2303224120. PubMed ID: 37695905
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial
Hebert JD; Tang YJ; Andrejka L; Lopez SS; Petrov DA; Boross G; Winslow MM
bioRxiv; 2024 Mar; ():. PubMed ID: 38496564
[TBL] [Abstract][Full Text] [Related]
4. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo.
Rogers ZN; McFarland CD; Winters IP; Naranjo S; Chuang CH; Petrov D; Winslow MM
Nat Methods; 2017 Jul; 14(7):737-742. PubMed ID: 28530655
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of the PTEN/NMAC1 gene associated with frequent chromosomal loss detected using comparative genomic hybridization in endometrial cancer.
Hirai Y; Tanaka N; Furuta R; Kawaguchi T; Sakamoto M; Shirahama S; Noda T
Gynecol Oncol; 2001 Oct; 83(1):81-8. PubMed ID: 11585417
[TBL] [Abstract][Full Text] [Related]
6. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
McFadden DG; Politi K; Bhutkar A; Chen FK; Song X; Pirun M; Santiago PM; Kim-Kiselak C; Platt JT; Lee E; Hodges E; Rosebrock AP; Bronson RT; Socci ND; Hannon GJ; Jacks T; Varmus H
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6409-E6417. PubMed ID: 27702896
[TBL] [Abstract][Full Text] [Related]
7. Topological evidence of differential oncogene activation-tumor suppressor gene inactivation features in 10 human neoplasias, as revealed by sequential regression analysis of world cancer incidence data.
Kodama M; Murakami M; Kodama T
Anticancer Res; 1997; 17(5B):3809-16. PubMed ID: 9427785
[TBL] [Abstract][Full Text] [Related]
8. Efficient and multiplexed somatic genome editing with Cas12a mice.
Hebert JD; Xu H; Tang YJ; Ruiz PA; Detrick CR; Wang J; Hughes NW; Donosa O; Andrejka L; Karmakar S; Aboiralor I; Tang R; Sage J; Cong L; Petrov DA; Winslow MM
bioRxiv; 2024 May; ():. PubMed ID: 38496463
[TBL] [Abstract][Full Text] [Related]
9. Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation.
Aiderus A; Contreras-Sandoval AM; Meshey AL; Newberg JY; Ward JM; Swing DA; Copeland NG; Jenkins NA; Mann KM; Mann MB
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435458
[TBL] [Abstract][Full Text] [Related]
10. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
11.
Hayashi T; Desmeules P; Smith RS; Drilon A; Somwar R; Ladanyi M
Clin Cancer Res; 2018 Mar; 24(6):1436-1447. PubMed ID: 29127119
[No Abstract] [Full Text] [Related]
12. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
14. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
15. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary accessibility of mutational pathways.
Franke J; Klözer A; de Visser JA; Krug J
PLoS Comput Biol; 2011 Aug; 7(8):e1002134. PubMed ID: 21876664
[TBL] [Abstract][Full Text] [Related]
17. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
18. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
19. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma.
Gutmann DH; McLellan MD; Hussain I; Wallis JW; Fulton LL; Fulton RS; Magrini V; Demeter R; Wylie T; Kandoth C; Leonard JR; Guha A; Miller CA; Ding L; Mardis ER
Genome Res; 2013 Mar; 23(3):431-9. PubMed ID: 23222849
[TBL] [Abstract][Full Text] [Related]
20. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Lin PC; Yeh YM; Hsu HP; Chan RH; Lin BW; Chen PC; Pan CC; Hsu KF; Hsiao JR; Shan YS; Shen MR
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
